ClinicalTrials.gg
CompletedNCT07214740Updated Dec 17, 2025

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

A Phase 3 interventional study of APL-2, Pegcetacoplan in Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
74th of 107
44 · median 98
Started
2025
with 19 others
Phase 3
15 of 131
2 open now
Registered
120th of 131
by date
Lead sponsor
8 of 131
Apellis Pharmaceuticals, Inc.

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 74th largest by enrollment of the 107 interventional ones that give a count, is one of 20 that started in 2025, is one of 15 in phase 3, and was the 120th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This is a phase 3, open-label study to evaluate the safety of pegcetacoplan in a prefilled syringe (PFS)

03

Conditions studied

  • Geographic Atrophy Secondary to Age-related Macular Degeneration

Keywords

  • Geographic Atrophy
  • Age-Related Macular Degeneration
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be aged at least 60 years and have a diagnosis of GA secondary to AMD.
  2. Participants must have adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images in the study eye as determined by the retina specialist.
  3. Study eye must be deemed to be indicated for IVT pegcetacoplan therapy at the discretion of the retina specialist.
  4. Female participants must be women of nonchildbearing potential, defined as women with 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (eg, age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks prior to screening/baseline. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of .
  5. Male participants must be surgically sterile or must agree to use protocol-defined highly effective methods of and to refrain from donating sperm from screening through the duration of the study and for 90 days after their dose of study drug.
  6. Participants must be willing and able to provide and comply with the study visit schedule and study-related procedures/requirements.

Exclusion criteria

Exclusion Criteria:

  1. Retinal atrophy secondary to a condition other than AMD, such as Stargardt disease, cone rod dystrophy, or toxic maculopathies like plaquenil maculopathy, in either eye.
  2. Any history or active CNV associated with AMD or any other cause, including any evidence of RPE rips or evidence of neovascularization anywhere based on spectral domain optical coherence tomography imaging as assessed by the retina specialist.
  3. Presence of an active ocular disease in the study eye that, in the opinion of the investigator, compromises or confounds visual function, including but not limited to, uveitis and other macular diseases (eg, epiretinal membrane, full thickness macular hole, or uncontrolled glaucoma/ocular hypertension); benign conditions in the opinion of the investigator, such as peripheral retina dystrophy, are not exclusionary.
  4. IOP >21 mm Hg in the study eye at the screening/baseline visit.
  5. Participants who have legal blindness or worse vision in study eye (ie, best-corrected visual acuity [BCVA] of ≤35 Early Treatment Diabetic Retinopathy Study letters).
  6. History of laser therapy in the macular region of study eye.
  7. Any intraocular surgery in the study eye at any time during the past 3 months.
  8. Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention during the study period or, in the opinion of the investigator, could compromise visual function during the study period.
  9. Any prior extended-release therapeutic agent, or ocular drug-release device implantation (approved or , including ) in the study eye.
  10. Active, suspected, or history of IOI in either eye at the screening/baseline visit.
  11. Any to IVT injection, including current ocular or periocular infection.
  12. Current systemic infectious disease or a therapy for active infectious disease.
  13. History of IVT injection in the study eye within 90 days or 5 half-lives of the product (other than IVT pegcetacoplan), whichever is longer, prior to the screening/baseline visit
  14. Participation in an investigational product or medical device study (other than IVT pegcetacoplan studies) within 90 days or 5 half-lives of the product, whichever is longer, prior to the screening/baseline visit.
  15. Known to pegcetacoplan or any of the in pegcetacoplan solution.
  16. Pregnancy or breastfeeding
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Pegcetacoplan, 15 mg/100 μL (single dose), intravitreal injection via prefilled syringe

    This is a 30-day, phase 3b, single-arm, open-label, multicenter study to evaluate the safety of IVT pegcetacoplan administered via PFS in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study consists of a screening/baseline visit at day 1, a follow-up call at day 7, and an end of study visit at day 30.

    Drug: APL-2, Pegcetacoplan

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate safety and tolerability of intravitreal (IVT) pegcetacoplan administered via PFS by assessing incidence of ocular treatment-emergent adverse events (TEAEs) in the study eye

    Time frame: Up to Day 30

Secondary outcomes

  1. The number of IVT pegcetacoplan injections successfully administered using PFS as reported by retina specialists immediately following the injection

    Time frame: At Day 1

07

Study locations

5 sites
  • California Retina Consultants
    Bakersfield, California 93309, United States
  • California Retina Consultants
    Oxnard, California 93036, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Retina Consultants of Texas
    Katy, Texas 77494, United States
  • Retina Consultants of Texas
    Woodland, Texas 77384, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Dec 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2025
First posted
Oct 9, 2025
StartActual
Oct 24, 2025
Primary completionActual
Dec 12, 2025
CompletionActual
Dec 12, 2025
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07214740
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Oct 24, 2025
Primary completion
Dec 12, 2025
Completion
Dec 12, 2025
Last update
Dec 17, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion